Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan D Chow

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2021
On the Absence of SoundRyan D Chow
Trends in Cancer|May 1, 2018
Cancer CRISPR Screens In VivoRyan D Chow, Sidi Chen
Cancer Cell|March 17, 2023
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockadeEric Song, Ryan D Chow
Urologic Oncology|August 2, 2025
Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinomaRyan D Chow, Ronac Mamtani
Oncogene|August 4, 2018
Sno-derived RNAs are prevalent molecular markers of cancer immunityRyan D Chow, Sidi Chen
Clinical Genitourinary Cancer|September 7, 2025
Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial CarcinomaRyan D Chow, Ronac Mamtani
JAMA Oncology|November 13, 2025
Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial CancerRyan D Chow, Ramy Sedhom, Ronac Mamtani
Nature Communications|January 5, 2021
The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2Ryan D Chow, Medha Majety, Sidi Chen
Urologic Oncology|November 14, 2025
Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunctionHenry K Litt, Ronac Mamtani, Ryan D Chow
EMBO Reports|June 7, 2021
Epithelial cell plasticity: breaking boundaries and changing landscapesAleksandra Tata, Ryan D Chow, Purushothama Rao Tata
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2021
On the Absence of SoundRyan D Chow
Trends in Cancer|May 1, 2018
Cancer CRISPR Screens In VivoRyan D Chow, Sidi Chen
Cancer Cell|March 17, 2023
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockadeEric Song, Ryan D Chow
Urologic Oncology|August 2, 2025
Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinomaRyan D Chow, Ronac Mamtani
Oncogene|August 4, 2018
Sno-derived RNAs are prevalent molecular markers of cancer immunityRyan D Chow, Sidi Chen
Clinical Genitourinary Cancer|September 7, 2025
Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial CarcinomaRyan D Chow, Ronac Mamtani
JAMA Oncology|November 13, 2025
Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial CancerRyan D Chow, Ramy Sedhom, Ronac Mamtani
Nature Communications|January 5, 2021
The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2Ryan D Chow, Medha Majety, Sidi Chen
Urologic Oncology|November 14, 2025
Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunctionHenry K Litt, Ronac Mamtani, Ryan D Chow
EMBO Reports|June 7, 2021
Epithelial cell plasticity: breaking boundaries and changing landscapesAleksandra Tata, Ryan D Chow, Purushothama Rao Tata
Pageof 6